Back to results

Impact of Liraglutide 3.0 on Body Fat Distribution

Primary Purpose

Obesity, Visceral, Cardiovascular Diseases, Fat Disorder

Status

Completed

Phase

Phase 4

Locations

United States

Study Type

Interventional

Intervention

Liraglutide

Placebo

About this trial

This is an interventional prevention trial for Obesity, Visceral focused on measuring Obesity, Visceral, Cardiovascular Disease, Fat

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Age ≥ 35 years
Able to provide informed consent
BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with metabolic syndrome
Metabolic syndrome is defined as at least three of the following:3
1. waist circumference > 102 cm (40 in) in men and 88 cm (35 in) in women
2. triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia
3. HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women
4. blood pressure > 130/85 mmHg or on treatment for hypertension
5. fasting glucose > 100 mg/dL

Exclusion Criteria:

Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists (including liraglutide, exenatide or others as they become available), dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin within the last 3 months.
Receipt of any anti-obesity drug or supplement within 1 month prior to screening for this trial.
Self-reported or clinically documented history of significant fluctuations (>5% change) in weight within 3 months prior to screening for this trial.
History of diabetes mellitus (type 1 or 2) or on treatment with anti-diabetes medication.
History of chronic pancreatitis or idiopathic acute pancreatitis (current or prior history).
History of gallbladder disease (cholelithiasis or cholecystitis).
Chronic kidney disease stage III or greater (eGFR<60 mL/min).
Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome).
Current or history of treatment with medications that may cause significant weight gain, within 1 month prior to screening for this trial, including systemic corticosteroids (except for a short course of treatment, i.e., 7- 10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g., imipramine, amitryptiline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium).
Diet attempts using herbal supplements or over-the-counter medications within 1 month prior to screening for this trial.
Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial.
Participation in a clinical trial within the last 3 months prior to screening for this trial.
Familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
Personal history of non-familial medullary thyroid carcinoma.
History of Major Depressive Disorder within the last 2 years.
History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder.
Any lifetime history of a suicide attempt.
A history of any suicidal behavior in the last month prior to randomization.
Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the Investigator.
Known or suspected hypersensitivity to trial product(s) or related product(s).
Known or suspected abuse of alcohol or narcotics.
Language barrier, mental incapacity, unwillingness or inability to understand.
Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. These include abstinence and the following methods: diaphragm with spermicide, condom with spermicide (by male partner), intrauterine device, sponge, spermicide, Norplant®, Depo-Provera® or oral contraceptives.

Sites / Locations

University of Texas Southwestern Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Liraglutide 3.0 mg

Placebo

Arm Description

Drug: Liraglutide Active Drug Other Names: Saxenda Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection.

Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL Other Names: Placebo Saline injection Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection.

Outcomes

Primary Outcome Measures

Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI

The effect on relative percent reduction from baseline in visceral adipose tissue mass measured by MRI after 40 weeks on treatment. Positive numbers reflect the reduction in the value from baseline to study endpoint as a percent of the baseline. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Secondary Outcome Measures

Absolute Reduction in Visceral Adipose Tissue Volume

The effect on absolute reduction from baseline in visceral adipose tissue mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Relative Percent Reduction in Body Weight

The effect on relative percent reduction from baseline in body weight after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Absolute Reduction in Body Weight

The effect on absolute reduction from baseline in body weight after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Relative Percent Reduction in Waist Circumference

The effect on relative percent reduction from baseline in waist circumference after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Absolute Reduction in Waist Circumference

The effect on absolute reduction from baseline in waist circumference after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Relative Percent Reduction in Total Body Adipose Tissue

The effect on relative percent reduction from baseline in total body adipose tissue (fat) mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Absolute Reduction in Total Body Adipose Tissue

The effect on absolute reduction from baseline in total body adipose tissue mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Relative Percent Reduction in Abdominal Subcutaneous Adipose Tissue

The effect on relative percent reduction from baseline in abdominal subcutaneous adipose tissue mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Absolute Reduction in Abdominal Subcutaneous Adipose Tissue

The effect on absolute reduction from baseline in abdominal subcutaneous adipose tissue mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Relative Percent Reduction in Lower Body Subcutaneous Adipose Tissue

The effect on relative percent reduction from baseline in lower body subcutaneous adipose tissue mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Absolute Reduction in Lower Body Subcutaneous Adipose Tissue

The effect on absolute reduction from baseline in lower body subcutaneous adipose tissue mass measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Relative Percent Reduction in Liver Fat Percent

The effect on relative percent reduction from baseline in liver (hepatic) fat percentage measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Negative values reflect an increase in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Absolute Reduction in Liver Fat Percent

The effect on absolute reduction from baseline in liver (hepatic) fat percentage measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Negative values reflect an increase in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower cardiovascular risk.

Relative Percent Reduction in Total Body Lean Volume

The effect on relative percent reduction from baseline in total body lean volume (fat-free mass) measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Absolute Reduction in Total Body Lean Volume

The effect on absolute reduction from baseline in total body lean volume (fat-free mass) measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Relative Percent Reduction in Total Thigh Muscle Volume

The effect on relative percent reduction from baseline in total thigh muscle volume measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Absolute Reduction in Total Thigh Muscle Volume

The effect on absolute reduction from baseline in total thigh muscle volume measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint.

Relative Percent Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

The effect on relative percent reduction from baseline in mean anterior thigh muscle fat infiltration percent measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Negative values reflect an increase in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower risk for metabolic disease.

Absolute Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

The effect on absolute reduction from baseline in mean anterior thigh muscle fat infiltration percent measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. Negative values reflect an increase in the value from baseline to study endpoint. Reduction in this variable is believed to be associated with lower risk for metabolic disease

Change From Baseline in VAT/SAT Ratio

The effect on absolute reduction from baseline in Visceral adipose tissue/subcutaneous adipose tissue (VAT/SAT) ratio measured by MRI after 40 weeks on treatment versus placebo. Positive numbers reflect the reduction in the value from baseline to study endpoint. This is the ratio of visceral adipose tissue to subcutaneous adipose tissue and it is thought that lower values (relatively less visceral adipose tissue) are better.

Change From Baseline in Total Fat/Fat-free Mass Ratio

The effect on absolute change from baseline in total fat/fat-free mass ratio measured by MRI after 40 weeks on treatment versus placebo. This is a ratio of fat to lean mass and it is believed that lower values (less fat relative to lean mass) is better.

Relative Percent Change in Fasting Blood Glucose

The relative percent change in fasting blood glucose from baseline to study end point as a percent of baseline by treatment group. Negative values reflect a reduction. This is a blood based biomarker for diabetes in which normal levels are desirable (70-100 mg/dL).

Relative Percent Change in Insulin

The relative percent change in insulin from baseline to study end point as a percent of baseline by treatment group. Positive values reflect an increase. Collection was impacted by coronavirus disease 2019 (COVID-19) and limitations to in person study visits, limiting complete collection of data for this measure. This is a blood based biomarker in which lower fasting levels are desirable.

Relative Percent Change in HOMA-IR

The relative percent change in HOMA-IR from baseline to study end point as a percent of baseline by treatment group. Positive values reflect an increase. Collection was impacted by coronavirus disease 2019 (COVID-19) and limitations to in person study visits, limiting complete collection of data for this measure. The relative percent change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) from baseline to study end point by treatment group measures insulin resistance. Levels above 1.9 signal early insulin resistance, while levels above 2.9 signal significant insulin resistance. There will be optimal insulin sensitivity if HOMA-IR is less than 1.

Relative Percent Change in C-reactive Protein

The relative percent change in biomarker of inflammation: C-reactive protein (CRP) from baseline to study end point as a percent of baseline by treatment group. Negative values reflect a decrease. Collection was impacted by coronavirus disease 2019 (COVID-19) and limitations to in person study visits, limiting complete collection of data for this measure. This is a blood based test for which lower values are associated with less inflammation and lower risk for cardiovascular events.

Relative Percent Change in Triglyceride/HDL-C Ratio

The relative percent change in triglyceride/HDL-C ratio from baseline to study end point as a percent of baseline by treatment group. Negative values reflect a decrease. Collection was impacted by coronavirus disease 2019 (COVID-19) and limitations to in person study visits, limiting complete collection of data for this measure. Lower ratio of triglycerides to HDL-cholesterol is associated with less insulin resistance and lower cardiovascular risk.

Relative Percent Change in Nt-proBNP

The relative percent change in N-terminal Pro Brain Natriuretic Peptides (Nt-proBNP) from baseline to study end point as a percent of baseline by treatment group. Negative values reflect a decrease. Collection was impacted by coronavirus disease 2019 (COVID-19) and limitations to in person study visits, limiting complete collection of data for this measure. NT-proBNP is a blood based biomarker. Lower levels are associated with lower risk for heart failure and cardiovascular events.

Absolute Change in Fasting Blood Glucose

The change in fasting blood glucose from baseline to study end point by treatment group.

Absolute Change in Insulin

The absolute change in insulin from baseline to study end point by treatment group. Collection was impacted by COVID-19 and changes to study visits.

Absolute Change in HOMA-IR

The absolute change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) from baseline to study end point by treatment group measures insulin resistance. Levels above 1.9 signal early insulin resistance, while levels above 2.9 signal significant insulin resistance. There will be optimal insulin sensitivity if HOMA-IR is less than 1. Collection was impacted by COVID-19 and changes to study visits.

Absolute Change in CRP

The change in Markers of inflammation: C-reactive protein (CRP) from baseline to study end point by treatment group. Collection was impacted by COVID-19 and changes to study visits. This is a blood based test for which lower values are associated with less inflammation and lower risk for cardiovascular events.

Absolute Change in Triglyceride/HDL-C Ratio

The change in triglyceride/HDL-C ratio from baseline to study end point by treatment group. Collection was impacted by COVID-19 and changes to study visits. Lower ratio of triglycerides to HDL-cholesterol is associated with less insulin resistance and lower cardiovascular risk.

Absolute Change in Nt-proBNP

The change in N-terminal Pro Brain Natriuretic Peptides (Nt-proBNP) from baseline to study end point by treatment group. Collection was impacted by COVID-19 and changes to study visits. NT-proBNP is a blood based biomarker. Lower levels are associated with lower risk for heart failure and cardiovascular events.

Change From Baseline in Heart Rate

The change in heart rate/pulse from baseline to study endpoint visit by treatment group.

Change From Baseline in Blood Pressure

The change in systolic blood pressure from baseline to study endpoint visit by treatment group.

Full Information

NCT ID

NCT03038620

First Posted

January 30, 2017

Last Updated

October 20, 2021

Sponsor

University of Texas Southwestern Medical Center

Collaborators

Novo Nordisk A/S

1. Study Identification

Unique Protocol Identification Number

NCT03038620

Brief Title

Impact of Liraglutide 3.0 on Body Fat Distribution

Official Title

Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease

Study Type

Interventional

2. Study Status

Record Verification Date

October 2021

Overall Recruitment Status

Completed

Study Start Date

January 2017 (Actual)

Primary Completion Date

October 13, 2020 (Actual)

Study Completion Date

October 13, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

University of Texas Southwestern Medical Center

Collaborators

Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

5. Study Description

Brief Summary

This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks on-treatment.

Detailed Description

Obesity has long been recognized as a risk factor for all-cause mortality and morbidity, including the development of cardiovascular and metabolic diseases such as coronary artery disease, hypertension, insulin resistance, diabetes, and dyslipidemia. Obesity has recently been formally defined as a chronic disease characterized by pathophysiological processes that result in increased adipose tissue mass and can result in increased morbidity and mortality. Although the health risks associated with obesity are clear, there is an emerging appreciation that obesity per se, as defined by simple anthropometric measures such as waist circumference or body mass index (BMI), is neither necessary nor sufficient to promote cardiometabolic disease and atherosclerotic cardiovascular disease (ASCVD) risk. As a result, BMI alone is an insufficient marker of risk and may not accurately identify individuals at elevated risk for ASCVD. There is a pressing need to more accurately phenotype obesity to identify individuals at elevated risk for ASCVD that may benefit from more intensive preventive and therapeutic strategies

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Obesity, Visceral, Cardiovascular Diseases, Fat Disorder

Keywords

Obesity, Visceral, Cardiovascular Disease, Fat

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 4

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

235 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Liraglutide 3.0 mg

Arm Type

Experimental

Arm Description

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Intervention Type

Drug

Intervention Name(s)

Liraglutide

Other Intervention Name(s)

Saxenda

Intervention Description

Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.

Intervention Type

Drug

Intervention Name(s)

Placebo

Other Intervention Name(s)

Saline injection

Intervention Description

Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.

Primary Outcome Measure Information:

Title

Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI

Description

Time Frame

Baseline, 40 weeks

Secondary Outcome Measure Information:

Title

Absolute Reduction in Visceral Adipose Tissue Volume

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Body Weight

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Body Weight

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Waist Circumference

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Waist Circumference

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Total Body Adipose Tissue

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Total Body Adipose Tissue

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Abdominal Subcutaneous Adipose Tissue

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Abdominal Subcutaneous Adipose Tissue

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Lower Body Subcutaneous Adipose Tissue

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Lower Body Subcutaneous Adipose Tissue

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Liver Fat Percent

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Liver Fat Percent

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Total Body Lean Volume

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Total Body Lean Volume

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Total Thigh Muscle Volume

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Reduction in Total Thigh Muscle Volume

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

Description

Time Frame

Baseline,40 weeks

Title

Absolute Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

Description

Time Frame

Baseline,40 weeks

Title

Change From Baseline in VAT/SAT Ratio

Description

Time Frame

Baseline, 40 weeks

Title

Change From Baseline in Total Fat/Fat-free Mass Ratio

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Change in Fasting Blood Glucose

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Change in Insulin

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Change in HOMA-IR

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Change in C-reactive Protein

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Change in Triglyceride/HDL-C Ratio

Description

Time Frame

Baseline, 40 weeks

Title

Relative Percent Change in Nt-proBNP

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Change in Fasting Blood Glucose

Description

The change in fasting blood glucose from baseline to study end point by treatment group.

Time Frame

Baseline,40 weeks

Title

Absolute Change in Insulin

Description

The absolute change in insulin from baseline to study end point by treatment group. Collection was impacted by COVID-19 and changes to study visits.

Time Frame

Baseline, 40 weeks

Title

Absolute Change in HOMA-IR

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Change in CRP

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Change in Triglyceride/HDL-C Ratio

Description

Time Frame

Baseline, 40 weeks

Title

Absolute Change in Nt-proBNP

Description

Time Frame

Baseline, 40 weeks

Title

Change From Baseline in Heart Rate

Description

The change in heart rate/pulse from baseline to study endpoint visit by treatment group.

Time Frame

Baseline, 40 weeks

Title

Change From Baseline in Blood Pressure

Description

The change in systolic blood pressure from baseline to study endpoint visit by treatment group.

Time Frame

Baseline, 40 weeks

Other Pre-specified Outcome Measures:

Title

On-treatment Time, Weeks

Description

The mean duration of treatment during study follow-up.

Time Frame

weeks

10. Eligibility

Sex

All

Minimum Age & Unit of Time

35 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age ≥ 35 years Able to provide informed consent BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with metabolic syndrome Metabolic syndrome is defined as at least three of the following:3 waist circumference > 102 cm (40 in) in men and 88 cm (35 in) in women triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women blood pressure > 130/85 mmHg or on treatment for hypertension fasting glucose > 100 mg/dL Exclusion Criteria: Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists (including liraglutide, exenatide or others as they become available), dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin within the last 3 months. Receipt of any anti-obesity drug or supplement within 1 month prior to screening for this trial. Self-reported or clinically documented history of significant fluctuations (>5% change) in weight within 3 months prior to screening for this trial. History of diabetes mellitus (type 1 or 2) or on treatment with anti-diabetes medication. History of chronic pancreatitis or idiopathic acute pancreatitis (current or prior history). History of gallbladder disease (cholelithiasis or cholecystitis). Chronic kidney disease stage III or greater (eGFR<60 mL/min). Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome). Current or history of treatment with medications that may cause significant weight gain, within 1 month prior to screening for this trial, including systemic corticosteroids (except for a short course of treatment, i.e., 7- 10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g., imipramine, amitryptiline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium). Diet attempts using herbal supplements or over-the-counter medications within 1 month prior to screening for this trial. Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial. Participation in a clinical trial within the last 3 months prior to screening for this trial. Familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. Personal history of non-familial medullary thyroid carcinoma. History of Major Depressive Disorder within the last 2 years. History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder. Any lifetime history of a suicide attempt. A history of any suicidal behavior in the last month prior to randomization. Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the Investigator. Known or suspected hypersensitivity to trial product(s) or related product(s). Known or suspected abuse of alcohol or narcotics. Language barrier, mental incapacity, unwillingness or inability to understand. Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. These include abstinence and the following methods: diaphragm with spermicide, condom with spermicide (by male partner), intrauterine device, sponge, spermicide, Norplant®, Depo-Provera® or oral contraceptives.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Parag Joshi, MD

Organizational Affiliation

University of Texas Southwestern Medical Center

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of Texas Southwestern Medical Center

City

Dallas

State/Province

Texas

ZIP/Postal Code

75390

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Citations:

PubMed Identifier

19853906

Citation

Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum In: Lancet. 2010 Mar 20;375(9719):984.

Results Reference

background

PubMed Identifier

21844879

Citation

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum In: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322.

Results Reference

background

PubMed Identifier

18340209

Citation

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Fernando Costa. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2005 Dec;4(4):198-203. doi: 10.1097/00132577-200512000-00018. No abstract available.

Results Reference

background

PubMed Identifier

21121834

Citation

Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9. doi: 10.1056/NEJMoa1000367. Erratum In: N Engl J Med. 2011 Sep 1;365(9):869.

Results Reference

background

PubMed Identifier

22949540

Citation

Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012 Sep 4;126(10):1301-13. doi: 10.1161/CIRCULATIONAHA.111.067264. No abstract available.

Results Reference

background

PubMed Identifier

25253227

Citation

Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G; The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014 Sep;20(9):977-89. doi: 10.4158/EP14280.PS. No abstract available.

Results Reference

background

PubMed Identifier

24345592

Citation

Morkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag Health Study), Norway. J Am Coll Cardiol. 2014 Mar 25;63(11):1071-8. doi: 10.1016/j.jacc.2013.11.035. Epub 2013 Dec 15.

Results Reference

background

PubMed Identifier

18356555

Citation

Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1039-49. doi: 10.1161/ATVBAHA.107.159228. Epub 2008 Mar 20. Erratum In: Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):e151.

Results Reference

background

PubMed Identifier

21865361

Citation

McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011 Nov;96(11):E1756-60. doi: 10.1210/jc.2011-0615. Epub 2011 Aug 24.

Results Reference

background

PubMed Identifier

17549449

Citation

McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, Reaven GM, Cushman SW. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia. 2007 Aug;50(8):1707-15. doi: 10.1007/s00125-007-0708-y. Epub 2007 Jun 5.

Results Reference

background

PubMed Identifier

17707180

Citation

See R, Abdullah SM, McGuire DK, Khera A, Patel MJ, Lindsey JB, Grundy SM, de Lemos JA. The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. J Am Coll Cardiol. 2007 Aug 21;50(8):752-9. doi: 10.1016/j.jacc.2007.04.066. Epub 2007 Aug 6.

Results Reference

background

PubMed Identifier

24582192

Citation

Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO, Ebbert JO, English DR, Gapstur SM, Giles GG, Horn-Ross PL, Park Y, Patel AV, Robien K, Weiderpass E, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Hartge P, Bernstein L, Berrington de Gonzalez A. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014 Mar;89(3):335-45. doi: 10.1016/j.mayocp.2013.11.011.

Results Reference

background

PubMed Identifier

16182882

Citation

Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62. doi: 10.1016/S0140-6736(05)67402-8. No abstract available.

Results Reference

background

PubMed Identifier

25538311

Citation

Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2015 Jan;38(1):150-8. doi: 10.2337/dc14-2391. No abstract available.

Results Reference

background

PubMed Identifier

23687099

Citation

Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring). 2013 Sep;21(9):E439-47. doi: 10.1002/oby.20135. Epub 2013 May 19.

Results Reference

background

PubMed Identifier

22990274

Citation

Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012 Sep 19;308(11):1150-9. doi: 10.1001/2012.jama.11132.

Results Reference

background

PubMed Identifier

25190234

Citation

Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, Khera A, McGuire DK, de Lemos JA, Turer AT. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014 Sep 9;64(10):997-1002. doi: 10.1016/j.jacc.2014.05.057.

Results Reference

background

PubMed Identifier

23929898

Citation

Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A, McGuire DK, Vega GL, Grundy SM, de Lemos JA, Drazner MH. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging. 2013 Sep;6(5):800-7. doi: 10.1161/CIRCIMAGING.113.000532. Epub 2013 Aug 8.

Results Reference

background

PubMed Identifier

23850922

Citation

Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol. 2013 Sep 3;62(10):921-5. doi: 10.1016/j.jacc.2013.06.027. Epub 2013 Jul 10.

Results Reference

background

PubMed Identifier

23812094

Citation

Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013 Nov;37(11):1443-51. doi: 10.1038/ijo.2013.120. Epub 2013 Jul 1. Erratum In: Int J Obes (Lond). 2013 Nov;37(11):1514. Int J Obes (Lond). 2015 Jan;39(1):187.

Results Reference

background

PubMed Identifier

26768490

Citation

Borga M, Thomas EL, Romu T, Rosander J, Fitzpatrick J, Dahlqvist Leinhard O, Bell JD. Validation of a fast method for quantification of intra-abdominal and subcutaneous adipose tissue for large-scale human studies. NMR Biomed. 2015 Dec;28(12):1747-53. doi: 10.1002/nbm.3432. Epub 2015 Nov 2.

Results Reference

background

PubMed Identifier

25808071

Citation

Schaudinn A, Linder N, Garnov N, Kerlikowsky F, Bluher M, Dietrich A, Schutz T, Karlas T, Kahn T, Busse H. Predictive accuracy of single- and multi-slice MRI for the estimation of total visceral adipose tissue in overweight to severely obese patients. NMR Biomed. 2015 May;28(5):583-90. doi: 10.1002/nbm.3286. Epub 2015 Mar 25.

Results Reference

background

PubMed Identifier

25343445

Citation

Dong Z, Luo Y, Zhang Z, Cai H, Li Y, Chan T, Wu L, Li ZP, Feng ST. MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects. PLoS One. 2014 Oct 24;9(10):e111283. doi: 10.1371/journal.pone.0111283. eCollection 2014.

Results Reference

background

PubMed Identifier

24871333

Citation

Thomas MS, Newman D, Leinhard OD, Kasmai B, Greenwood R, Malcolm PN, Karlsson A, Rosander J, Borga M, Toms AP. Test-retest reliability of automated whole body and compartmental muscle volume measurements on a wide bore 3T MR system. Eur Radiol. 2014 Sep;24(9):2279-91. doi: 10.1007/s00330-014-3226-6. Epub 2014 May 29.

Results Reference

background

PubMed Identifier

15810802

Citation

Human energy requirements: report of a joint FAO/ WHO/UNU Expert Consultation. Food Nutr Bull. 2005 Mar;26(1):166. No abstract available.

Results Reference

background

PubMed Identifier

34358471

Citation

Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, Rodder S, Pandey A, Joshi PH. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):595-605. doi: 10.1016/S2213-8587(21)00179-0. Epub 2021 Aug 3.

Results Reference

derived

Learn more about this trial

Impact of Liraglutide 3.0 on Body Fat Distribution

We'll reach out to this number within 24 hrs